ABIOMED, Inc.  

(Public, NASDAQ:ABMD)   Watch this stock  
Find more results for ABMD
62.19
+1.40 (2.30%)
After Hours: 62.65 +0.46 (0.74%)
Mar 2, 6:30PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 60.67 - 62.65
52 week 20.29 - 62.65
Open 61.55
Vol / Avg. 0.00/591,547.00
Mkt cap 2.51B
P/E 144.87
Div/yield     -
EPS 0.43
Shares 41.11M
Beta 1.55
Inst. own 104%
Apr 29, 2015
Q4 2015 Abiomed Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 4, 2015
Abiomed Inc at Cowen Health Care Conference - 11:20AM EST - Add to calendar
Feb 11, 2015
Abiomed Inc at Leerink Global Healthcare Conference
Jan 28, 2015
Q3 2015 Abiomed Inc Earnings Call
Jan 27, 2015
Q3 2015 Abiomed Inc Earnings Release
Dec 3, 2014
Abiomed Inc at Piper Jaffray Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 20.46% 4.00%
Operating margin 22.04% 4.55%
EBITD margin - 5.92%
Return on average assets 22.30% 3.92%
Return on average equity 27.41% 4.81%
Employees 511 -
CDP Score - -

Address

22 CHERRY HILL DR
DANVERS, MA 01923
United States - Map
+1-978-7775410 (Phone)
+1-978-7778411 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ABIOMED, Inc. is a provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients. The Company develops, manufacture and market products that are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company's products are used in the cardiac catheterization lab (cath lab) by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. The Impella 2.5 is introduced with normal interventional cardiology procedures and can pump up to 2.5 liters of blood per minute. The Company is conducting USpella, the United States multicenter observational registry collecting clinical data and outcomes for general use patients supported with Impella 2.5, CP and 5.0 during procedures.

Officers and directors

Michael R. Minogue Chairman of the Board, President, Chief Executive Officer
Age: 47
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Robert L. Bowen Chief Financial Officer, Vice President, Treasurer
Age: 64
Bio & Compensation  - Reuters
David M. Weber Chief Operating Officer
Age: 52
Bio & Compensation  - Reuters
William J. Bolt Senior Vice President - Global Product Operations
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Andrew J. Greenfield Vice President, General Manager - Global Marketing
Age: 41
Bio & Compensation  - Reuters
Michael G. Howley Vice President, General Manager - Global Sales and Marketing
Age: 50
Bio & Compensation  - Reuters
Ingrid Goldberg Director - Investor Relations
Bio & Compensation  - Reuters
Dorothy E. Puhy Lead Independent Director
Age: 62
Bio & Compensation  - Reuters
Eric A. Rose M.D. Director
Age: 63
Bio & Compensation  - Reuters
W. Gerald Gerald Austen M.D. Independent Director
Age: 84
Bio & Compensation  - Reuters